Literature DB >> 4974308

Congenital dysfibrinogenemia: fibrinogen Detroit.

E F Mammen, A S Prasad, M I Barnhart, C C Au.   

Abstract

A 17 yr old female with a congenital bleeding disorder was found to suffer from dysfibrinogenemia. Whole blood and plasma coagulation times were delayed and thrombelastograms were grossly abnormal. Clottability of plasma fibrinogen by addition of thrombin was not demonstrated during the 30 min test period. Fibrinogen was revealed by turbidometric and immunologic techniques. Other coagulation factors were present in normal amounts and prothrombin activation was normal. Patient's plasma inhibited thrombin clotting times of normal plasma and purified normal fibrinogen. Fibrinolysis was not detected. The plasma fibrinogen migrated normally on paper and cellulose acetate electrophoresis, but on immunoelectrophoresis it displayed a faster mobility than normal fibrinogen. On immunodiffusion the antigenic determinants were similar to those of normal fibrinogen. The patient's fibrinogen-antifibrinogen precipitins required longer to appear and the resultant precipitin was broader and hazier than those elicited with normal fibrinogen. These findings suggest the presence of two discrete populations of fibrinogen molecules. Investigation of the family of the patient suggested that the defect has an autosomal dominant pattern of heredity. Immunologic comparisons of our patient's plasma and of her relatives with plasma of patients with "Fibrinogen Baltimore" and "Fibrinogen Cleveland" revealed certain differences in immunoelectrophoretic mobility as well as in immunodiffusion. In keeping with the nomenclatures of abnormal fibrinogens in the literature, we propose the term "Fibrinogen Detroit" for this fibrinogen.Physicochemical properties of "Fibrinogen Detroit" were investigated also and compared with those of normal fibrinogen. Purified normal fibrinogen (clottability 96.7%) and "Fibrinogen Detroit" revealed homogeneity when studied by ultracentrifugation and immunoelectrophoresis. Native and cleaved "Fibrinogen Detroit" had the same sedimentation constants and molecular weights as the normal. In fresh samples. 3 moles of free SH groups/mole of fibrinogen were titrated in both. Determination of the amino acid composition revealed a decreased content of lysine, glucosamine, and galactosamine in abnormal fibrinogen. Total carbohydrates, protein-bound hexoses, sialic acid, and hexosamine were decreased in the abnormal fibrinogen. In an investigation with Doctors Blombäck a specific molecular defect was revealed in the N-terminal disulfide knot of the alpha (A) chain in which the arginine at the 19th position was replaced by serine. It is believed that the substitution of a strongly basic amino acid with a neutral hydroxy acid may result in considerable conformational changes in the N-terminal disulfide knot of fibrinogen which might affect the "active site" for polymerization. The lower carbohydrate content observed in "Fibrinogen Detroit" may have been the result of a change in primary and tertiary structure of the protein.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4974308      PMCID: PMC322215          DOI: 10.1172/JCI105980

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Turbidimetric method of fibrinogen assay; results with the Coleman Junior spectrophotometer.

Authors:  A H FOWELL
Journal:  Am J Clin Pathol       Date:  1955-03       Impact factor: 2.493

2.  [Studies on a case of congenital afibrinogenemia. (On the role of blood coagulation in hemostasis)].

Authors:  R GROSS; G SCHICK; N LANG; D NIES; B RAHN; M BECKER; H HENGSTMANN
Journal:  Klin Wochenschr       Date:  1963-07-15

3.  Pathogenesis of the coagulation defect developing during pathological plasma proteolytic ("fibrinolytic") states. II. The significance, mechanism and consequences of defective fibrin polymerization.

Authors:  N ALKJAERSIG; A P FLETCHER; S SHERRY
Journal:  J Clin Invest       Date:  1962-04       Impact factor: 14.808

4.  Profibrinolysin, antifibrinolysin, fibrinogen and urine fibrinolytic factors in the human subject.

Authors:  M M GUEST
Journal:  J Clin Invest       Date:  1954-11       Impact factor: 14.808

5.  Analysis of hexose phosphates and sugar mixtures with the anthrone reagent.

Authors:  L C MOKRASCH
Journal:  J Biol Chem       Date:  1954-05       Impact factor: 5.157

6.  Seromucoid and the bound carbohydrate of the serum proteins.

Authors:  C Rimington
Journal:  Biochem J       Date:  1940-06       Impact factor: 3.857

7.  The role of the carbohydrate moiety in bovine fibrinogen.

Authors:  K LAKI; L MESTER
Journal:  Biochim Biophys Acta       Date:  1962-02-12

8.  The purple color reaction given by diphenylamine reagent. I. With normal and rheumatic fever sera.

Authors:  W AYALA; L V MOORE; E L HESS
Journal:  J Clin Invest       Date:  1951-07       Impact factor: 14.808

9.  [Hemorrhagic diathesis with dominant heredity, caused by an abnormal fibrinogen (fibrinogen Baltimore)].

Authors:  E A Beck; M W Mosesson; P Charache; D P Jackson
Journal:  Schweiz Med Wochenschr       Date:  1966-09-17

10.  THE UTILIZATION OF L-GLUCOSE BY MAMMALIAN TISSUES AND BACTERIA.

Authors:  H Rudney
Journal:  Science       Date:  1940-08-02       Impact factor: 47.728

View more
  14 in total

1.  Congenital dysfibrinogenemias: molecular abnormalities of fibrinogen.

Authors:  E F Mammen
Journal:  Blut       Date:  1976-10

Review 2.  Hereditary disorders of blood coagulation due to defective and deficient synthesis of protein.

Authors:  D P Jackson
Journal:  Trans Am Clin Climatol Assoc       Date:  1971

3.  Molecular deficiencies of human blood coagulation.

Authors:  E A Beck
Journal:  Experientia       Date:  1972-01-15

4.  Chromatographic, ultracentrifugal, and related studies of fibrinogen "Baltimore".

Authors:  M W Mosesson; E A Beck
Journal:  J Clin Invest       Date:  1969-09       Impact factor: 14.808

5.  Functional evaluation of an inherited abnormal fibrinogen: fibrinogen "Baltimore".

Authors:  E A Beck; J R Shainoff; A Vogel; D P Jackson
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

6.  Fibrinogen Marburg a new genetic variant of fibrinogen.

Authors:  G Fuchs; R Egbring; K Havemann
Journal:  Blut       Date:  1977-02

7.  Fibrinogen Baltimore II: congenital hypodysfibrinogenemia with delayed release of fibrinopeptide B and decreased rate of fibrinogen synthesis.

Authors:  R F Ebert; W R Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

8.  Fibrinogen St. Louis: a new inherited fibrinogen variant, coincidentally associated with hemophilia A.

Authors:  L A Sherman; L W Gaston; M E Kaplan; A R Spivack
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

9.  Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers.

Authors:  A P Laudano; R F Doolittle
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

10.  Radioimmunoassay of human fibrinopeptide A.

Authors:  H L Nossel; L R Younger; G D Wilner; T Procupez; R E Canfield; V P Butler
Journal:  Proc Natl Acad Sci U S A       Date:  1971-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.